Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

of Plicera pending the results of the ongoing Phase 2 trial.

AT2220 (1-deoxynojirimycin HCl) for the treatment of Pompe Disease

As previously reported, the Company suspended enrollment for the Phase 2 clinical trial of its investigational drug AT2220 for the treatment of Pompe Disease and received notice from the U.S. Food and Drug Administration (FDA) that the trial is on clinical hold.

The Company continues to work closely with the FDA to determine appropriate next steps for advancing the development of AT2220 and expects to provide guidance on this progress over the upcoming months.

Additionally, Amicus continues to be encouraged with its preclinical studies with AT2220 in combination with ERT. As previously announced, the Company expects to report additional data from these activities throughout the remainder of 2009.

Preclinical Chaperone Programs

Amicus continues to invest in research to assess the potential for applying its versatile chaperone technology platform to the treatment of a broad range of human genetic diseases. As part of this effort, Amicus continues to conduct preclinical studies in Parkinson's disease and is investing in new research aimed at evaluating disease targets for other neurodegenerative and genetic disorders.

Appointment of New Director

The Company announced today the election of James Barrett, Ph.D., to its Board of Directors. Dr. Barrett currently serves as General Partner of New Enterprise Associates (NEA), the Company's single largest shareholder, where he specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices, healthcare information systems and healthcare services companies. Prior to joining NEA in 2001, Dr. Barrett served as Founder, Chairman and CEO of Sensors for Medicine and Science (1997 - 2001
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014  Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Terascala, the ... announced that Alan Swahn, a former vice president of ... team as vice president of marketing. Terascala’s software when ... and NetApp create the highest performance and most reliable ... appointed to guide Terascala’s channel expansion and broaden its ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and exhibition ... at Double Tree by Hilton Beijing, China is all ... & Bioanalytical research methods only to facilitate improved living ... Dr. Srinubabu Gedela, MD of OMICS Group Inc has ... one in bringing a unique and international mix of ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... BioCryst,Pharmaceuticals (Nasdaq: BCRX ) today announced ... Chief Medical Officer of BioCryst, effective July 1,2008. ... recently,serving as Vice President of North American Medical ... Officer Dr. Tom Simon, who has been with,the ...
... use Nuevolution,s Chemetics(R) Technology for Lead Discovery, ... it has entered into a drug discovery collaboration ... its proprietary Chemetics(R) drug discovery,technology to identify novel ... to Merck. The Chemetics(R) platform uses innovative DNA,labeling ...
... Pa., June 17 MEDRAD, INC., announced ... a new Fluorodeoxyglucose (FDG),Infusion System for Positron ... Intego(TM) PET Infusion System is the,first infusion ... automate the FDG,delivery process., (Logo: ...
Cached Biology Technology:William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals 2William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals 3William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals 4Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc. 2MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System 2MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System 3
(Date:7/11/2014)... Shenzhen, July 10, 2014---A team of researchers from The ... have identified a gene of wild soybean linked to ... to grow in saline soil. This study published online ... to unveil novel genomic information for crop improvement. , ... to domestication and human selection, cultivated soybeans have less ...
(Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
(Date:7/11/2014)... other group members to reduce aggression and gain access ... for grooming activities shows a certain pattern across the ... journal Biology Letters . , Grooming between individuals ... ulterior motives. To be groomed has hygienic benefits and ... individual can provide access to infants, mating opportunities and ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2A new genome editing method brings the possibility of gene therapies closer to reality 2Baboons groom early in the day to get benefits later 2
... to Josef Ackermann, the head of Deutsche Bank. At almost ... in Rome. The hand of the manager in charge of ... or security staff have had to conduct painstaking inspections of ... approach. At the end of 2011, though, the scanner T-Cognition ...
... release is available in German . ... from Siegen and Professor Jacek Błażewicz from Poznan have ... (DFG, German Research Foundation) and the Foundation for Polish ... scientific collaboration. "The two researchers perform outstanding research, are ...
... groundbreaking new gene sequencing technology, researchers have demonstrated that ... Acute Myeloid Leukemia, AML, one of the most common ... Pacific Biosciences, allows for the rapid and comprehensive detection ... findings, published online April 15 in Nature , ...
Cached Biology News:On the safe side: Contact-free analysis of chemical substances 2Copernicus Award 2012 for German-Polish collaboration in business information systems 2Copernicus Award 2012 for German-Polish collaboration in business information systems 3Scientists identify FLT3 gene as a valid therapeutic target in acute myeloid leukemia 2
... product contains 5 ml Dynabeads Tosylactivated (4.5 ... (tosyl) reactive groups. For coupling of antibodies ... on initial coupling with covalent binding of ... sulphydryll groups (SH)) occurringovernight. Coupling reactions can ...
Carrier-Free Recombinant Human Flt-3/Flk-2 Ligand (Flt3/Flk2 Ligand, Flt3L, Flt3-L, Flk2L, Flk2-L) 100 ug...
... II inhibitor (IC50 = 59.2 M). ... H 32 O 13 MolWeight: ... RT CAS: ... Soluble to 100 mM in DMSO ...
NAP-2 (5C7)...
Biology Products: